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Background: Mesenchymal stromal cell (MSC)-based cytotherapies fuel the hope for
reduction of chronic systemic immunosuppression in allotransplantation, and our group
has previously shown this capability for both swine and human cells. MSCs harvested
from distinct anatomical locations may have different behavior and lead to different
outcomes in both preclinical research and human trials. To provide an effective reference
for cell therapy studies, we compared human and porcine MSCs from omental fat
(O-ASC), subcutaneous fat (SC-ASC) and bone marrow (BM-MSC) under rapid culture
expansion with endothelial growth medium (EGM).
Methods: MSCs isolated from pigs and deceased human organ donors were compared
for yield, viability, cell size, population doubling times (PDT), surface marker expression
and differentiation potential after rapid expansion with EGM. Immunosuppressant toxicity
on MSCs was investigated in vitro for four different standard immunosuppressive drugs.
Immunomodulatory function was compared in mixed lymphocyte reaction assays (MLR)
with/without immunosuppressive drug influence.
Results: Human and porcine omental fat yielded significantly higher cell numbers than
subcutaneous fat. Initial PDT was significantly shorter in ASCs than BM-MSCs and similar
thereafter. Viability was reduced in BM-MSCs. Porcine MSCs were positive for CD29,
CD44, CD90, while human MSCs expressed CD73, CD90 and CD105. All demonstrated
confirmed adipogenic differentiation capacity. Cell sizes were comparable between
groups and were slightly larger in human cells. Rapamycin revealed slight, mycophenolic
acid strong and significant dose-dependent toxicity on viability/proliferation of almost
all MSCs at therapeutic concentrations. No relevant toxicity was found for Tacrolimus
and Cyclosporin A. Immunomodulatory function was dose-dependent and similar
between groups. Immunosuppressants had no significant adverse effect on MSC
immunomodulatory function.
Schweizer et al. MSCs From Distinct Donor Locations
Discussion: MSCs from different harvest locations and donor species differ in terms
of isolation yields, viability, PDT, and size. We did not detect relevant differences in
immunomodulatory function with or without the presence of immunosuppressants.
Human and pig O-ASC, SC-ASC and BM-MSC share similar immunomodulatory
function in vitro and warrant confirmation in large animal studies. These findings should
be considered in preclinical and clinical MSC applications.
Keywords: adipose-derived stromal cells, bone marrow stromal cells, endothelial growth medium,
immunomodulation, omentum majus, immunosupressants, mixed lymphocyte reaction, transplantation
INTRODUCTION
Mesenchymal stem cells (MSCs) are well-known for their
beneficial potential in a variety of conditions since discovery
of their multi-facetted ability to proliferate, differentiate,
heal, regenerate and modulate (1). Due to their paracrine
immunomodulatory function (2–4), different MSC types are
increasingly used in transplantation as cell adjuncts paired to
conditioning and maintenance regimens in an attempt to reduce
the burdens of immunosuppression after allotransplantation and
promote durable graft tolerance (5–7): intensive preclinical and
clinical research is carried out to establish such new successful
protocols in small and large animals.
Inherent advantages of ASCs over their bone-marrow
counterpart have shifted the focus accordingly (8, 9). Beside
the abundance and ease of access of fat depots in patients to
harvest the cells from, ASCs are also supposed to be superior in
terms of immunomodulatory function (8). Clearly, MSCs from
distinct anatomical sources can potentially differ significantly
in proliferative, differentiation and immunomodulatory
capacity, to name a few, which has to be considered while
performing preclinical, but also clinical studies including cell
therapies (10–15).
Not only the anatomical cell origin is of relevance, but also
the species may have impact on the functionality of MSCs: while
porcine and human MSCs seem to possess similar characteristics
suggesting that results can be extrapolated from preclinical
studies and be applied to clinical protocols (16), other studies
suggest different behavior of porcine MSCs compared to human
cells (17).
Cell-based therapies for tolerance induction in transplantation
are usually applied in conjunction with immunosuppressants
employed as conditioning or maintenance medication, and these
may indeed have an influence on viability and function of
the applied cells. It has been shown previously that drugs
such as mycophenolic acid (MPA) and rapamycin (Rapa) can
disturb viability and proliferation of MSCs (18), but on the
other hand also act synergistically as found with cyclosporin A
(CsA) (19, 20).
Abbreviations: ASC, adipose-derived mesenchymal stem cell; BM-MSC, bone
marrow MSC; CsA, cyclosporin A; IS, systemic immunosuppression; MLR, mixed
lymphocyte reaction assay; MPA, mycophenolic acid; MSC, mesenchymal stem
(stromal) cell; O-ASC, omental ASC; PDT, population doubling time; Rapa,
rapamycin; RT, room temperature; SC-ASC, subcutaneous ASC; SVF, Stromal
vascular fraction; Tac, tacrolimus; WBC, white blood cells.
Here, we aimed at directly comparing porcineMSCs harvested
from three distinct anatomical locations head-to-head to their
counterpart of human origin in vitro in terms of isolation yields,
proliferation, immunosuppressive function, and susceptibility to
different immunosuppressive agents, using a rapid expansion
culture strategy including endothelial growth factor 2 (EGM-
2) medium.
MATERIALS AND METHODS
Donors and Tissue Harvesting
Animals
The cells were isolated from domestic Yorkshire pigs post-
mortem (n = 7). The animals were euthanized by means of
lethal pentobarbital injections and placed supine on an operating
table. The isolation process was performed in a sterile fashion
and the skin was scrubbed with betadine solution three times
prior to skin incision. After an inguinal skin incision, all the
subcutaneous inguinal fat was excised and placed in sterile
containers. The tissue was irrigated with Ringer lactate to avoid
any drying. Afterwards, a median laparotomy was performed
and the whole omentum majus exposed and excised, then placed
in a sterile container irrigated with Ringers lactate. Afterwards,
the hind limb long-bones were harvested and cut-open at one
end with an oscillating saw. The bone marrow was then flushed
with RPMI-1640 with L-Glutamine (Fisher Scientific) directly
in sterile containers. Data regarding isolation summarized in
Table 1. The tissues were then immediately transferred to the cell
isolation lab for further processing.
Human Donors
Deceased tissue donors were referred after informed consent by
the Center for Organ Recovery and Education (CORE). All tissue
donors (n= 6) were brain-dead cadaveric solid organ donors and
de-identified. Inclusion criteria were 18–65 years of age male and
female subjects. Exclusion criteria were the presence of hepatitis
B, C, or HIV, sepsis/positive serology results. Adipose tissue from
abdominal subcutaneous fat and omental fat (300–500 g) was
excised under sterile conditions after solid organ retrieval. Bone
marrow (30mL) was aspirated from the iliac crest using an 11-G
J-style aspiration kit (DePuy Synthes, ProcureTM). Data regarding
isolation summarized in Table 1. Sampling was approved by
the Committee for Oversight of Research and Clinical Training
Involving Descents (CORID No. 475).
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PORCINE DONORS (n = 7)
3.8 ± 1.0 49.43 ± 11.3 112.9 ± 36.4 44.71 ± 7.3 4 ± 0.0 8.9 ± 8.8 19.4 ± 17.0 13.8 ± 1.6
HUMAN DONORS (n = 6)
45.1 ± 13.8 88.5 ± 18.6 115 ± 45 110 ± 43.6 35.5 ± 15 8.9 ± 4.4 30.7 ± 15 12.4 ± 5.2
Tissue weights and cell numbers at isolation.
Cell Isolation
Porcine
For isolation of SC-ASC and O-ASC, the tissues were minced
with sterile scissors and handled with sterile forceps under
a laminar flow hood until a relatively homogenous fat mass
was obtained. The tissues were distributed into 50mL conical
tubes at 5mL aliquots and 35mL of sterile enzymatic solution
added. The enzymatic solution was composed of type II
collagenase (Worthington Biochemical Corp, Lakewood, NJ,
USA), Proteinase K (Sigma-Aldrich) and Hanks’ balanced saline
solution (HBSS; Fisher Scientific) (for 100mL of harvested fat:
1.4 g collagenase and 175mg proteinase in 700mL HBSS). The
tubes were placed in a shaking water bath at 37◦C for 90min.
Next, the digestate was filtered through 12-ply sterile gauze that
had been unfolded twice (final gauze filter was 3-ply). The tubes
were centrifuged at 1,000 rpm for 10min. at room temperature
(RT) and supernatant discarded. 10mL red blood cell (RBC) lysis
buffer (NH4Cl, A-0171; KHCO3; P-7682; EDTA, E-5134, all from
Sigma; pH adjusted to 7.4, solution with de-ionized water) was
added to each tube and cell pellets were disrupted by pipetting up
and down gently. Lysates from 4 tubes were combined into 50mL
tube yielded approximately 40mL buffer per tube. Additional
gauze filtration was used as needed. Tubes were centrifuged
again at 1,000 rpm for 10min. at RT and supernatant discarded.
Cells were resuspended in endothelial growth factor 2 medium
(EGM-2MV, Lonza, CC-3156 & CC-4147) supplemented
with penicillin/streptomycin 1% (Invitrogen), gentamycin
1% (Invitrogen) and amphotericin B 1% (initial seeding
only; Invitrogen), counted and either plated or immediately
cryopreserved in freezing medium (DMSO10%/FBS90%).
The cells were initially seeded at 10,000/cm2. After overnight
incubation for cell attachment, non-adherent cells were removed
using a PBS (Sigma-Aldrich) wash (culture incubator at 37◦C,
5% CO2, 95–98% humidity). For BM-MSC isolation, the solution
with the flushed bone marrow was added to an equal part of
enzymatic digestion solution and placed in a shaking water
bath at 37◦C for 30min. After that, the isolation process was
identical to the above-mentioned ASC isolation. The cells were
initially seeded at 100,000/cm2 and washed with PBS the day
after. The cells were allowed to get to 80–90% confluence and
then harvested by means of 0.25% trypsin (Corning). MSCs were
always counted by an automated, calibrated counting machine
(Countess machine and Countess R© Cell Counting Chamber
Slides, Invitrogen) and re-plated at 5,000 cells/cm2 in T175 or
T75 flasks (Corning), 20 or 10mL were added, respectively, to
the flasks and changed thrice weekly. Amphotericin B was added
during the first plating to avoid any fungal infection and then
withdrawn at the first passaging.
Human
SC- and O-ASCs were isolated according to our established
protocol (21). Briefly, adipose tissue was minced and digested
in type II collagenase solution in a water bath at 37◦C with
gentle agitation for ∼30min. The digested tissue was then
filtered through sterile gauze and centrifuged at 1,500 rpm for
10min. The cell pellet was suspended in erythrocyte lysis buffer
and centrifuged at 1,500 rpm for 10min. The pellet was then
suspended in EGM as described above and filtered through sterile
gauze to eliminate any cellular debris. Further processing and
culture were the same as for porcine cells.
BM-MSCs were isolated according to a protocol previously
published by Wolfe et al. (22). Briefly bone marrow aspirate
was diluted in Hanks balanced salt solution, gently overlaid on
Ficoll Paque Plus (GE-Healthcare) and centrifuged at 1,800 g for
30min. After collection of the cloudy layer the cells were re-
suspended with Hanks Balanced Salt Solution and centrifuged
again at 1,000 g for 10min. The cell pellet was suspended in EGM
and plated overnight. Medium was changed the day after, and the
cell culturing continued as described above.
Cell Surface Marker Analysis
Passage 2 to 3 MSCs were lifted by means of trypsin, counted
and put in sterile Falcon tubes at aliquots of 1× 106 cells/tube at
least. The following antibody panel was used for characterization
of porcine cells: CD14 (AbD Serotec), CD29 (BD Pharmingen),
CD31 (BD Biosciences), CD34 (Abcam + Goat anti-rabbit
IgG (PE-cy5.5), Life Technologies), CD44 (Biolegend), CD45
(Genway Biotech), CD73 (Biolegend), CD90 (BD Biosciences),
CD105 (Bioss Antibodies), CD146 (Genetex). For human
cells, following antibodies were used CD45, CD90, CD105,
CD73, CD235a, CD34 (BD Biosciences), CD31 (BioLegend),
CD33, CD14 (Beckman Coulter), and CD146 (Miltenyi Biotec)
(antibodies summarized in Tables 2, 3). The cells were stained
with the antibodies singularly and according to manufacturer’s
protocol and were assessed using a BD LSRII flow cytometer,
analyzing at least 20,000 events (Becton Dickinson, Franklin
Lakes, NJ, USA). The obtained data was analyzed with FlowJo
software (TreeStar Inc., Ashland, OR, USA).
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TABLE 2 | Porcine panel.
Marker Dye Vendor
CD14 FITC AbD Serotec
CD29 Alexa Fluor® 647 BD Bioscience
CD31 PE BD Bioscience
CD34 PE-cy5.5 Ig-G Abcam/Life Technologies (Dye)*
CD44 Alexa Fluor 700 Biolengend
CD45 DyLight®680 Genway Biotech
CD73 Brilliant Violet 421 Biolegend
CD90 DyLight®755 BD Bioscience
CD105 PE-cy7 Bioss Antibodies
CD146 FITC Genetex
Antibodies for flow cytometry phenotyping of porcine cells.
*CD34 was conjugated with PE-cy5.5. All other antibodies already delivered conjugated
to mentioned dye.
TABLE 3 | Human panel.
Marker Dye Vendor
CD14 PC5 Beckman coulter
CD31 PE-Cy7 Biolegend
CD33 PC5 Beckman coulter
CD34 AF700 BD bioscience
CD45 APC-Cy7 BD bioscience
CD73 PE BD bioscience
CD90 APC BD bioscience
CD105 FITC BD bioscience
CD146 VioBlue Miltenvi biotec
CD235a PE-Cy5 BD bioscience
Antibodies for flow cytometry phenotyping of human cells.
All antibodies already delivered conjugated to mentioned dye.
Viability and Proliferation
For all the cell lines in culture, cell numbers were recorded at
each passage and re-seeded at 5,000 cells/cm2. Proliferation was
assessed until passage 7. The population doubling time (PDT)
was calculated using following equation: time/log2(harvested
cells/seeded cells) (23). Viability was assessed by tryptan
blue (Invitrogen) exclusion at each passage and expressed
as percentage.
Adipogenic Differentiation Assays
Mesenchymal stem cells derived from the same
individual/animal were plated at passage 3 at a density of
40,000 cells/cm2 in 96-well plates using EGM. After 24 h,
medium was replaced with adipogenic differentiation medium
[STEMPRO R© Adipogenesis Differentiation Kit (Invitrogen)]
that was changed every 3–4 days over the course of 2 weeks.
Control cells were cultured in regular EGM for 2 weeks that was
changed every 3–4 days. After 2 weeks the cells were the washed
with PBS and each well was filled with 200 µL PBS with addition
of 5 µL Adipored R© staining solution and incubated for 10min.
The fluorescence readout was performed using a microplate
reader (Infinite R© 200 PRO NanoQuant, Tecan). After readout,
cells were imaged with bright-field microscopy.
Mixed Lymphocyte Reaction Assays
Responder splenocytes were isolated from spleens of naïve pigs
and human donors and were stimulated by phytohemagglutinin
(PHA; Sigma-Aldrich). In the suppressor assay, 200,000 cells/well
MSCs were added at different ratios to responder cells, namely
at 1:4, 1:8, and 1:16, in 96-well plates with round bottom.
Co-cultures were performed in triplicates until confluence
(3–5 days) with RPMI-1640 medium supplemented with L-
Glutamine. To assess splenocyte proliferation, the cells were
pulsed with [3H]thymidine (1 mCi/well) for the final 8 h
and [3H]thymidine incorporation was measured as counts per
minute in a liquid scintillation counter (Perkin Elmer). A
total of 6 and 3 experiments were performed for porcine and
human MLRs, respectively. For MLR testing under influence
of immunosuppressants, the MSCs were incubated with the
different compounds for 36 h and then added to MLR as
described above. Following, clinically relevant concentrations
were used for these experiments: 10 ng/mL (Tac), rapamycin
10 ng/mL (Rapa), Cyclosporin A 250 ng/mL (CsA).
Toxicity Assays
The following drugs were used (all Sigma-Aldrich, St. Louis,
MO, USA): tacrolimus (T-049), rapamycin (S-015), cyclosporin
A (30024), and mycophenolic acid (M3536; MPA). AlamarBlue
(AbD Serotec) was quality-controlled as suggested by the
manufacturer and optimal cell seeding density and incubation
time determined. Positive and negative controls were performed.
A stock solution was created for each drug and then serially
diluted. 5000 cells/well were seeded in 96-well plates (Corning)
and incubated with the drugs for 36 h. Experiments were
performed in quadruplicates and passage 3 to 4 cells were used.
Following serial dilutions were used: Tac and Rapa 0 – 2 - 10 – 50
– 250 - 1250 ng/ml, CsA 0 – 10 – 50 – 250 – 1250 - 6250 ng/ml,
and MPA 0 – 0.2 – 1 – 5 – 25 – 125 ug/ml. Sole addition of PBS
served as control. At the end of incubation, 20 µl AlamarBlue
was added to each well and incubated for 5 h. After that, 200
µl of supernatant were transferred from each well to a new,
black 96-well plate with clear flat bottom (Fisher Scientific) and
directly assessed for fluorescence in a plate reader (Tecan Infinite
M200 Pro). A total of 8 readings per well was performed and
mean calculated.
Cell Size Measurement
Plates with detached cells were imaged and under an
Axiovert 25 microscope (Carl Zeiss Microscopy GmbH)
as described previously (24). Calibration occurred with a
glass hemocytometer. Cell sizes were calculated with ImageJ
software (National Institute of Health, Bethesda, MD, USA).
For that purpose, at least 100 cells/sample were measured and
means calculated.
Statistical Analysis
Prism 8.0 (GraphPad, San Francisco, CA, USA) was used for
statistical analysis. Data are presented as means ± SD unless
otherwise specified. Differences between the groups were assessed
by unpaired t-test (two groups), or one-way/two-way ANOVA
with Tukey post-test (multiple groups). P < 0.05 was considered
statistically significant.
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RESULTS
Cell Isolation
O-SVF of both porcine and human origin showed the highest
yields per mL of tissue (pO-SVF 0.49 ± 0.4 and hO-SVF
0.894 ± 0.05 x106/mL tissue), significantly higher than the SC
counterpart (pSC-SVF 0.076 ± 0.05 and hSC-SVF 0.154 ±
0.09 × 106/mL tissue; p < 0.001 vs. p/hO-SVF; Figure 1A).
Since no exact amount of tissue could be retrieved for BM-
MSC after flushing the long bones, isolation yields could not
be calculated.
Cell yields after passaging the cultured SVF showed a trend
for higher numbers in pO-ASC and pSC-ASC compared to BM-
MSC (37,390± 16,268 and 39,859± 21,606 vs. pBM-MSC 22,917
± 9,814 cells/cm2; n.s.). For human cells, however, there was a
statistically significant higher proliferation in O-ASC and SC-
ASC compared to their BM counterpart (hO-ASC 33,973 ±
2,936, and hSC-ASC 29,695 ± 1,336; p < 0.001 and p < 0.0001
vs. BM-MSC 18,070± 2,712 cells/cm2; Figure 1B).
While SVF viability upon isolation was comparable between
O-SVF and SC-SVF from both porcine and human donors (pO-
SVF 94.31 ± 5.15%, pSC-SVF 89.87 ± 11.89%, hO-SVF 96.25 ±
1.89%, hSC-SVF 92.5 ± 3.78%; p>0.05; Figure 1C), porcine and
human BM-SVF revealed reduced viability (pBM-SVF 85.25 ±
8.97%, and hBM-SVF 84.75± 5.43%; p < 0.05 vs. p/hO-SVF).
Cell Culture
While first passage PDT was significantly longer in BM cells
(pBM-MSC 96.80± 3.86 h, hBM-MSC 76.37± 5.98 h) compared
to O- and SC-MSC (pO-ASC 55.1± 14.71 h, p< 0.001; pSC-ASC
50.36 ± 16.53h, p < 0.0001; hO-ASC 49.33 ± 6.78 h, p < 0.0001;
hSC-ASC 49.3 ± 3.01h, p < 0.0001 vs. BM-MSC), the following
PDT up to passage 7 was lower and comparable between the cells
FIGURE 1 | Cell isolation. (A) Cell yields after isolation following specific protocols for each cell type. The resulting cell population after isolation is the so called
≪stromal vascular fraction≫ (SVF). BM-MSC are not displayed since no precise tissue amount could be determined due to flushing. Expressed in number of cells per
mL of harvested tissue. Cross = mean, whiskers = 5–95 percentile. (B) Cell yields after first passaging of plated cells at a density of 10,000 cells/cm2, passaged at
80–90% confluency. Expressed in number of cells per cm2. Cross = mean, whiskers = 5–95 percentile. (C) Viability of freshly isolated cells as determined by Tryptan
blue exclusion. Expressed in viable cell % of total cells. Error bars = SD. Unpaired t-test. *p < 0.05, ***p < 0.001, ****p < 0.0001.
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of different origin (Figure 2A). There was a trend for longer PDT
for passage 7 in all groups beside pSC-ASC (pO-ASC 47.04 ±
21.59 h, pSC-ASC 22.40 ± 3.95 h, pBM-MSC 47.60 ± 30.40 h,
hO-ASC 40.85 ± 8.49 h, hSC-ASC 41.70 ± 3.10 h, hBM-MSC
45.13± 5.84 h, n.s.).
Cell viability of porcine cells was comparable throughout
passaging up to passage 6, whereas at passage 7 there was a
decline in cell viability percent in BM-MSC group (86.50 ±
19.09% vs. pO-ASC 98.00± 2.09% and pSC-ASC 98.66± 1.15%;
p < 0.01). For human-derived cells, BM-MSCs had significantly
lower viability from passage 1 to 7 compared to O- and SC-ASCs
(Figure 2B).
Cell Surface Marker Analysis
All cells of porcine origin showed high expression of CD29,
CD44, and CD90, and negative for CD14, CD45, CD73, CD105,
and CD146, while showing low expression for CD31 and CD34.
Cells of human origin had a surfacemarker phenotype expressing
high levels of CD73, CD90, and CD105 and negative, or low
expression, for CD14, CD31, CD33, CD34, CD45, CD146, and
CD235 (Figure 3A). hBM-MSC showed a non-significant lower
expression of CD90 compared to hO-ASC and hSC-ASC (75.1±
17.09% vs. 88.22± 14.01% and 95.45± 2.80%).
Adipogenic Differentiation
Swine-derived cells showed no relevant difference in terms of
adipogenic differentiation potential between the cell types. X-
fold fluorescence increase compared to control was 8.53 ± 1.93
for pO-ASC, 7.56 ± 3.03 for pSC-ASC and 6.45 ± 1.28 for
pBM-MSC, respectively (n.s.; Figure 3B).
In contrast, in human cells there was a marked difference
between the cell types: the highest adipogenic differentiation was
in hO-ASC (20.27± 6.10 fold), followed by 14.95± 5.40 in hSC-
ASC and 4.20± 1.20 in hBM-MSC (p < 0.0001 and p < 0.001 vs.
O-ASC and SC-ASC; Figure 3B).
Cell Size Measurement
Mean porcine cell sizes did not differ between the groups and
were 13.93± 0.82µm in pO-ASC, 13.45± 0.35µm in pSC-ASC
and 13.98 ± 0.38µm in pBM-MSC. Compared to that, human
cells showed slightly higher mean sizes, significant only for BM-
MSCs (hO-ASC 17.70 ± 3.32µm, hSC-ASC 16.26 ± 3.96µm,
FIGURE 2 | Cell culture. (A) Population doubling times (PDT) are shown for the three cell lines (O-ASC, SC-ASC, and BM-MSC) over 7 passages. Median ±
interquartile range, expressed in hours. (B) The cell viability is displayed up to passage 7 for the three porcine and human cell lines (O-ASC, SC-ASC and BM-MSC)
during culture with endothelial growth medium (EGM-2MV, Lonza). Determined by Tryptan blue exclusion. Cells lifted at 80–90% confluency. Expressed in %. Error
bars = SD. One-way ANOVA with Tukey post-test. **p < 0.01, ***p < 0.001, ****p < 0.0001.
Frontiers in Immunology | www.frontiersin.org 6 May 2020 | Volume 11 | Article 826
Schweizer et al. MSCs From Distinct Donor Locations
FIGURE 3 | Cell surface marker phenotype and adipogenic differentiation. The three cell lines (O-ASC, SC-ASC, and BM-MSC) were analyzed for their surface marker
phenotype by flow cytometry (A; Bencton FACS Aria). CD73 showed no cross-reaction. Porcine cells: O-ASC n = 9, SC-ASC n = 7, BM-MSC n = 4 runs. Human
cells: O-ASC n = 4, SC-ASC n = 4, BM-MSC n = 3 runs. Expressed as %. Error bars = SD. Adipogenic differentiation assays were performed with passage 3 cells in
triplicates. Differentiation was quantified by fluorescence after Adipored® staining. (B left panel) Representative microscopic pictures. (B right panel) Results expressed
as x-fold increased intensity compared to controls. Error bars = SD. Two-way ANOVA with Tukey post-test. ***p < 0.001, ****p < 0.0001.
hBM-MSC 19.17± 3.30µm; hBM-MSC p< 0.05 vs. pBM-MSCs;
Figure 4).
Cell Immunomodulatory Function
All three porcine MSCs demonstrated immunomodulatory
function in vitro by reducing proliferation of allo-reactive
splenocytes in MLR assays after addition at different ratios.
O-ASC had the highest suppressive capacity, although not
significant, compared to SC-ASC and BM-MSC, which had
similar results. O-ASC (56.51 ± 8.51% at 4:1, 56.05 ± 20.38%
at 8:1, p < 0.0001 vs. control) and SC-ASC (68.09 ± 14.38%
and 65.12 ± 22.09%, for 4:1 and 8:1, respectively, p < 0.01
vs. control) had significant suppression at 4:1 and 8:1 ratios,
while BM-MSCs only at 4:1 ratio (58.21 ± 23.88%, p < 0.01
vs. control). At splenocyte-to-MSC ratio of 16:1 there was no
significant suppression in all three MSC lines (O-ASC 87.29 ±
16.97, SC-ASC 96.172± 12.31, BM-MSC 92.51± 10.98, p > 0.05
vs. control; Figure 5A).
Human cells, had a similar but stronger trend compared to
porcine-derived counterparts, with all cell types being able to
reduce allo-reactivitymore consistently in a dose-dependent way;
however, there was no significant difference between the groups
(O-ASC 4:1 31.64% ± 13.69, 8:1 60.50% ± 31.11, 16:1 72.12%
± 24.79; SC-ASC 4:1 40.92% ± 6.39, 8:1 64.21% ± 23.44, 16:1
72.27%± 23.91; BM-MSC 4:1 29.85%± 7.06 8:1 44.43%± 20.84
16:1 68.10% ± 33.27; all 4:1 p < 0.0001, O-ASC 8:1 p < 0.05 and
BM-MSC 8:1 p < 0.001 vs. control; Figure 5B).
Cell Susceptibility to Immunosuppressants
All cell types from swine and human donors showed no
significant differences in proliferation with Tac compared to
controls at any concentration. A similar picture was found
with CsA, but pO-ASC revealed a slight, yet significant higher
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FIGURE 4 | Cell size analysis. Diameters of lifted cells were measured in passage 2–3 cells for the three cell lines (O-ASC, SC-ASC, and BM-MSC). (A) Cell diameters
expressed in µm. Error bars = SD. One-way ANOVA with Tukey post-test. *p < 0.05. (B) Representative microscopic image of one cell in the hemocytometer
showing how diameters were manually measured with ImageJ (NIH). Bar = 20µm.
proliferation starting from 50 ng/mL upwards (110.80 ± 2.3%, p
< 0.01 vs. PBS; Figure 6).
In co-cultures with Rapa, however, there was a differential
effect on cell proliferation: while porcine O-ASCs were not
affected and human BM-MSCs only affected at high doses (87.55
± 3.77 at 50 and 77.95 ± 4.95% at 250 ng/mL), pSC-ASC and
pBM-MSC revealed diminished proliferation starting from Rapa
doses of 10 ng/mL (83.74 ± 2.13% p < 0.0001 vs. PBS) and
2 ng/mL (82.97 ± 3.23% p < 0.0001 vs. PBS), respectively,
which is including the therapeutic range. Similarly, in hO-ASC
proliferation decreased already from 2 ng/mL (86.73 ± 7.06%),
reaching significance at 50 ng/mL (84.80 ± 8.99% p < 0.05 vs.
PBS); in hSC-ASC accordingly, there was a disturbing effect on
proliferation from 10 ng/mL (83.88± 4.22% p < 0.0001 vs. PBS).
The most striking effect was seen in co-cultures with MPA: all
cell types were strongly affected already at doses of 0.2 ug/mL,
including therapeutic doses (pO-ASC 86.21 ± 0.80% 1 ng/mL p
< 0.001; pSC-ASC 71.35± 2.21%, pBM-MSC 73.27± 6.83% and
hSC-ASC 76.54± 5.99% 0.2 ug/mL p < 0.0001; hO-ASC 77.95±
16.79% 0.2 ug/mL p< 0.001; all vs. PBS). Only human BM-MSCs
were less affected and showed a trend for lower proliferation but
not as much as the other cell types.
Susceptibility of Cell Immunomodulatory
Function to Immunosuppressants
ASCs’ and BM-MSCs’ immunomodulatory function was not
significantly reduced in porcine cells when under the influence of
Tac, Rapa or CsA compared to PBS control. There was, however,
a minor reduction in suppression of allo-reaction with Tac (O-
ASC 41.21 ± 2.86% vs. PBS 32.82 ± 3.18%; SC-ASC 40.86 ±
2.53% vs. 26.28 ± 4.15% PBS; BM-MSC 52.36 ± 9.48% vs.
37.65 ± 41.23% PBS) and Rapa (O-ASC 51.09 ± 6.37%, SC-ASC
53.81 ± 3.35%; BM-MSC 56.76 ± 3.59%) in all groups and with
CsA only in O-ASC (56.96 ± 27.21%) and SC-ASC (47.22 ±
19.26%)(Figure 7A).
For human cells there were similar results with no significant
alteration of the immunomodulatory ability of ASCs and BM-
MSCs when co-cultured with the immunosuppressants. In hO-
ASC proliferation was 63.95 ± 13.56% with Tac, 43.77 ± 10.87%
with Rapa and 53.48 ± 3.81% with CsA vs. 79.00 ± 18.10% with
PBS (Figure 7B); in hSC-ASC it was 35.69 ± 24.41% with Tac,
54.05± 19.47% with Rapa and 50.92± 5.71% with CsA vs. 56.84
± 30.62% PBS. Finally, in hBM-MSCs proliferation was 65.43 ±
23.77%with Tac, 29.14± 17.96%with Rapa, 72.98± 19.54%with
CsA vs. 48.63± 17.11% PBS.
DISCUSSION
This study is unique in that it evaluated the potential
of MSCs for cytotherapies from three different anatomical
donor sites from both swine und human origin after rapid
culture-expansion with endothelial growth medium (EGM).
As main finding, there was no significant difference between
the three cell types in terms of immunomodulatory function
or susceptibility to immunosuppressive agents, making them
all ideal candidates for transplant-related cytotherapies in
conjunction with immunosuppressive agents at usual therapeutic
ranges. However, there are some advantages from an isolation,
cultivation and proliferative point of view for the omental and,
to a less extent, subcutaneous counterparts, which might favor
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FIGURE 5 | Immunosuppressive function. Mixed lymphocyte reaction assays (MLR) were performed to assess the immunomodulatory potential of the three cell lines
(O-ASC, SC-ASC, and BM-MSC) head-to-head of both porcine (A) and human (B) origin. Yorkshire splenocytes were stimulated with PHA and co-cultured with the
different cell lines for 3–5 days. Error bars = SD. Expressed as percentage proliferation in relation to positive control. Two-way ANOVA with Tukey post-test.
**p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control (splenocytes+PHA).
their use, even more so when accounting for ease of harvest
from these donor sites with low morbidity. The uniqueness
of the present study is seen also in the direct comparison of
the different cell lines between different species: the results
suggest that immunomodulatory function and cell susceptibility
to immunosuppressants found in swine are similar to that of
human cells, enabling extrapolation of results from large animal
studies to clinical application.
We used a rapid culture-expansion protocol to achieve high
cell yields in short culture time as proposed earlier by Suga
et al. (23). The use of EGM has not been previously published
with the three cell lines used in our study compared head-to-
head: our results suggest that in vitro MSCs from the three
sources retain typical surface marker phenotypes, differentiation
potential and immunomodulatory function under culture with
EGM. Depending on the application, the need for MSCs in high
numbers involves culture-expansion after cell isolation, prior to
administration to recipient. In the scenario of transplant-related
tolerogenic regimens, an early and repeated cell therapy with
MSCs from the same deceased tissue donor as the transplanted
organ might warrant better results (7, 25). Thus, rapid cell
expansion is key after tissues harvest and cell isolation from the
donors with genetic stability of the cells.
The use of omentum-derived ASCs in conjunction with
subcutaneous ASCs for transplant related purposes has been
proposed and investigated by our group previously (26). From
a translational aspect, the use of both SC- and O-ASCs warrant
increased cell yields and allow for high dosed cell therapy, while
acting synergistically in their immunomodulatory function.
Isolation yields in the O-ASC group were significantly higher
from porcine and human tissues compared to SC-ASC, even
though the amount of tissue harvested was usually less: this is
probably due to the loose nature of the omentum majus, which
makes disruption by the enzymatic solution more effective. In
general, there was high variability in the number of isolated
cells per volume from the omentum. Yields and viability at the
first passage were higher in O-ASC and SC-ASC, suggesting
that for BM-MSCs the actual isolation protocol is not able
to eliminate non-MSC cells adequately during isolation and
plating. Cell viability throughout cultivation to P7 was lower in
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FIGURE 6 | Susceptibility of MSCs to immunosuppressive agents. The three cell lines (O-ASC, SC-ASC, and BM-MSC) were exposed to 4 different
immunosuppressive agents commonly used in transplantation for 36 h to assess the effect on cell proliferation using AlamarBlue. Expressed in % viable cells
compared to control (no drug = vehicle+medium only). Error bars = SD. Red boxes indicate the approximate therapeutic ranges (Tacrolimus: 5–20 ng/mL,
Rapamycin 16–24 ng/mL, Cyclosporin A 100–400 ng/mL, Mycophenolic Acid 1-3.5 ug/L). Two-way ANOVA with Tukey post-test *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 vs. control (PBS only).
BM-MSC, significantly in human cells, under rapid expansion
with EGM.
In a study by Toyoda et al., isolation of human ASCs from
omentum majus and subcutis yielded fewer and more cells,
respectively, compared to our study, probably due to the differing
isolation protocol (12). As far it concerns pig-derived cells, Calle
et al. found that ASCs from abdominal fat have longer PDT than
their SC counterpart under culture with DMEM (27), which is
in contrast to similar PDT in O-ASC and SC-ASC in our study
under EGM. Other reports showed that BM-MSC had higher
PDT than ASCs in the past (28–30), which was confirmed only
in the first passage in our study.
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FIGURE 7 | Susceptibility of MSC immunosuppressive function to immunosuppressive agents. Mixed lymphocyte reaction assays (MLR) were performed to assess
the immunomodulatory potential of the three cell lines (O-ASC, SC-ASC, and BM-MSC) head-to-head of both porcine (A) and human (B) origin after incubation with
immunosuppressive agents at therapeutic dosage (Tacrolimus 10 ng/mL, Rapamycin 10 ng/mL, Cyclosporin A 250 ng/mL) for 36 h. Yorkshire splenocytes were
stimulated with PHA and co-cultured with the different cell lines at a 4:1 ratio. Expressed as percentage proliferation in relation to positive control. Error bars = SD.
Two-way ANOVA with Tukey post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control (splenocytes+PHA).
Presence of FGF-2, as in the EGM, has been shown to
promote ASC proliferation (31). Yoshimura et al. proposed ASC
expansion with EGM and compared it to standard medium, D-
MEM, in terms of multipotency and proliferation and found
rapid growth and multilineage differentiation potential under
EGM cultivation (23). They also suggested that FGF-2 might
be crucial for MSC self-renewal. While for the first passage
they demonstrated lower PDT, other than that we found similar
doubling times in the following passages for all three cell types.
Of note, porcine BM-MSC had the longest time to first passage
requiring almost 100 h to double the cell population, followed by
human BM-MSCs; however, in the following passages there was
no significant difference compared to other cell types. Another
study confirmed similar surface marker phenotype with EGM
comparable to standard cultivation media, whereas the in vivo
engraftment ability to the perivascular niche was increased with
EGM (32). MSCs in that study did not show an increase in
CD31 expression, suggesting that they did not differentiate in
alternative lineages up to passage 3 or 4 under EGM. We found
similar surface marker phenotype profiles as other groups (11, 27,
28, 30, 33) and there was no relevant difference between the cells.
CD73 is known for lack of cross-reactivity of the CD73 antibody
in pigs and was confirmed here (16, 34).
Although some authors reported similar adipogenic
differentiation potential in bone marrow and adipose
tissue derived MSCs (11), we found significantly increased
differentiation potential for human O-ASC and SC-ASC
compared to BM-MSC, as also found in other studies (35).
In pig cells, however, the difference was subtle, while there
was no significant difference between O-ASC and SC-ASC,
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even though other groups found higher affinity to adipogenic
differentiation in SC-ASC (12). Another study comparing three
different types of human ASCs found increased osteogenic
differentiation by omentum-derived cells, while subcutaneous
and pericardial derived cells had higher adipogenic potential
(14). In their study, the authors found also longer PDT in cells
from the pericardial niche. We did not explore chondrogenic
and osteogenic differentiation potential because we focused
on the immunomodulatory function and susceptibility of the
cells to immunosuppressants in this study: however, trilineage
differentiation potential has been shown in the past for the same
MSC types with similar surface marker phenotype for both
porcine and human-derived cells (14, 28, 29, 36).
There is a paucity of reports on the cell size for MSCs,
especially comparing different cell types. Our analysis revealed
slightly larger cell diameters in human MSCs compared to
porcine ones, especially for BM-MSCs. We could not identify
differences between the anatomical locations. Previously our
group analyzed detached rodent ASCs and MSCs and found
similar sizes for ASCs but larger diameters for BM-MSCs,
which might be due to inter-species differences or different
culture medium (24). Cell size is relevant mostly after
intravascular, usually intravenous, administration because of
potential entrapment of the cells in capillaries of organs such as
the lung, spleen and liver, which might reduce the amount of
MSCs reaching the target organ (37, 38). However, we did not
further investigate this in our study.
We assessed the immunomodulatory function of MSCs
from the different anatomical locations in vitro and found no
relevant inter-group difference in human and porcine cells,
while all cells exhibited dose-dependent suppression. To reach
a relevant suppressive function on activated splenocytes, at
least a splenocyte to MSC ratio of 8:1 was necessary for
porcine ASCs, and 8:1 for human ASCs. Li et al. found similar
suppressive effects between BM-MSCs and ASCs in MLRs with
PHA activation (28), which is in line with other groups (33)
and our results. Another group found that ASCs had higher
immunomodulatory capacity in MLRs with peripheral blood
mononuclear cells when compared to their BM counterpart (39).
In general, in that study they found much higher suppressive
capacity compared to our data, which might be due to
isolation and culture differences, or the different MLR setup
(peripheral blood mononuclear cells vs. splenocytes, CD3/CD28
activation against PHA). A study comparing human vs. porcine
BM-MSCs for cardiac allotransplantation could show similar
immunomodulatory action in vitro and in vivo (16).
The influence of immunosuppressive medications on MSCs
has been investigated previously: Hoogduijn et al. found that
MPA and Rapa inhibit MSC proliferation at therapeutic doses.
We were able to confirm these results for pig and human MSCs.
While pre-incubation of MSCs with Tac revealed an increased
immunosuppressive function according to Hoogduijn et al. (18),
we could not detect a relevant influence of the investigated
MSCs on immunomodulatory function. Moreover, similar to
our results, the same group found no difference in suppressive
function between human BM-MSCs and ASCs in vitro and in
vivo in a humanized mouse model (40). Putative advantages of
using CsA in conjunction with MSCs for immunomodulation as
suggested previously, could not be substantiated in vitro in our
study (19, 20). CsA has also been used successfully with porcine
ASCs in studies assessing their therapeutic effect in cardial
infarction (41). In the toxicity assays MSCs were afflicted by
reduced proliferation when incubated with Rapa andMPA, while
Tac and CsA did not impair cell growth. Interestingly, O-ASC of
porcine origin and human BM-MSCwere less susceptible to Rapa
andMPA, respectively. In previous own in vitro studies, we found
that anti-lymphocyte serum and Tac both dose-dependently
affected rodent ASC and MSC viability and proliferation already
at clinically relevant doses (24).
To investigate whether MSCs are influenced by the
immunosuppressants in their immunomodulatory functionality,
we incubated the cells with Tac, Rapa and CsA at a clinically
relevant dose in MLRs (MPA was excluded according to
toxicity assay results). We found no significant impact of the
different drugs on MSCs, but there was a non-significant trend
showing slight worse suppressive action of porcine MSCs under
immunosuppressant influence, while for human cells this was
not the case.
While the cell isolation method applied in this study was
not performed under a specific Food and Drug Administration
approved protocol, it is analogous to the process employed in
commercially available closed systems for cell isolation and has
been shown by our group to result in a similar cell product
as have been used in our own FDA sanctioned clinical trials
(42, 43). Furthermore, as cultivation and expansion is concerned,
we followed a strict, standardized and reproducible protocol,
warranting future translation to regulatory conformity and
similar to the type of expansion protocols used in cell therapy
clinical trials (44).
In summary, MSCs from omentum, subcutaneous
tissues, and bone marrow of both human and porcine
origin share similar behavior in terms of surface marker
phenotype, immunomodulatory function and susceptibility
to immunosuppressants. However, the data show superiority
of ASCs in isolation yields, viability and potential for rapid
culture-expansion. EGM culture expansion seems to retain the
functionality of both porcine and human MSCs, making is a
useful tool for cell therapy studies in which the necessary cell
dose exceeds the quantity of cells harvested.
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